Rituximab and antimetabolite treatment of granulomatous and lymphocytic interstitial lung disease in common variable immunodeficiency
- 1 February 2021
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 147 (2) , 704-712.e17
Abstract
No abstract availableKeywords
Funding Information
- Jeffrey Modell Foundation
- Children’s Hospital of Wisconsin Research Institute
This publication has 47 references indexed in Scilit:
- Morbidity and mortality in common variable immune deficiency over 4 decadesBlood, 2012
- Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel diseaseGenetics in Medicine, 2011
- Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID)Clinical Immunology, 2010
- The EUROclass trial: defining subgroups in common variable immunodeficiencyBlood, 2008
- Etanercept treatment of cutaneous granulomas in common variable immunodeficiencyJournal of Allergy and Clinical Immunology, 2006
- General considerations for lung function testingEuropean Respiratory Journal, 2005
- Immune abnormalities are a frequent manifestation of Kabuki syndromeAmerican Journal of Medical Genetics Part A, 2005
- Granulomatous-lymphocytic lung disease shortens survival in common variable immunodeficiencyJournal of Allergy and Clinical Immunology, 2004
- Lymphocyte subsets in healthy children from birth through 18 years of ageJournal of Allergy and Clinical Immunology, 2003
- Hypersensitivity pneumonitis in a patient with hypogammaglobulinemiaJournal of Allergy and Clinical Immunology, 1996